Novonesis is a publicly listed company tracked for investment-relevant business developments.
Novonesis addresses a $60B biosolutions market and $1T specialty chemicals market, growing high-single digits by outpacing end-markets 2-4x, with 37% EBITDA margins driven by pricing discipline (1-2% annual price contribution), 10% revenue R&D spend, 100K+ strain library, and AI-accelerated protein design; new frontiers include carbon capture, plastic recycling, and specialized proteins.